Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Recent developments in targeted therapies for chronic lymphocytic leukemia

Jacqueline Barrientos • 2 Jun 2015
ASCO 2015
Chronic Lymphocytic Leukemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, NY, provides a summary of recent developments in new therapeutic options for patients with chronic lymphocytic leukemia (CLL), including those with known complications, such as the presence of 17p deletion.

More from Jacqueline Barrientos

2:18
Advancements within the CLL treatment landscape
Jacqueline Barrientos • 13 Dec 2021
1:12
Novel treatment strategies for Richter’s transformation
Jacqueline Barrientos • 13 Dec 2021
2:37
Customizing CLL care with BTK Inhibitors
Jacqueline Barrientos • 13 Dec 2021
2:21
CAPTIVATE: Ibrutinib and venetoclax in CLL
Jacqueline Barrientos • 13 Dec 2021

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals